MA35064B1 - Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie - Google Patents

Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Info

Publication number
MA35064B1
MA35064B1 MA36364A MA36364A MA35064B1 MA 35064 B1 MA35064 B1 MA 35064B1 MA 36364 A MA36364 A MA 36364A MA 36364 A MA36364 A MA 36364A MA 35064 B1 MA35064 B1 MA 35064B1
Authority
MA
Morocco
Prior art keywords
thieno
pyrimidine derivatives
treating arrhythmia
arrhythmia
relates
Prior art date
Application number
MA36364A
Other languages
English (en)
French (fr)
Inventor
Derek Edward John
John Ford
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35064(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of MA35064B1 publication Critical patent/MA35064B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA36364A 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie MA35064B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (en) 2011-04-01 2012-03-29 Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia

Publications (1)

Publication Number Publication Date
MA35064B1 true MA35064B1 (fr) 2014-04-03

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36364A MA35064B1 (fr) 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Country Status (42)

Country Link
US (1) US9249155B2 (enExample)
EP (1) EP2694518B1 (enExample)
JP (1) JP5826374B2 (enExample)
KR (1) KR20140023332A (enExample)
CN (1) CN103492392B (enExample)
AP (1) AP2013007198A0 (enExample)
AR (1) AR088735A1 (enExample)
AU (1) AU2012235882B2 (enExample)
BR (1) BR112013025236A2 (enExample)
CA (1) CA2831493A1 (enExample)
CL (1) CL2013002789A1 (enExample)
CO (1) CO6801756A2 (enExample)
CR (1) CR20130488A (enExample)
CU (1) CU24173B1 (enExample)
CY (1) CY1117025T1 (enExample)
DK (1) DK2694518T3 (enExample)
EA (1) EA201301111A1 (enExample)
EC (1) ECSP13012988A (enExample)
ES (1) ES2558563T3 (enExample)
GB (1) GB201105659D0 (enExample)
GT (1) GT201300225A (enExample)
HR (1) HRP20151340T1 (enExample)
HU (1) HUE028438T2 (enExample)
IL (1) IL228555A0 (enExample)
MA (1) MA35064B1 (enExample)
ME (1) ME02314B (enExample)
MX (1) MX335937B (enExample)
NI (1) NI201300100A (enExample)
PE (1) PE20141021A1 (enExample)
PH (1) PH12013501952A1 (enExample)
PL (1) PL2694518T3 (enExample)
PT (1) PT2694518E (enExample)
RS (1) RS54458B1 (enExample)
RU (1) RU2013148627A (enExample)
SG (1) SG193578A1 (enExample)
SI (1) SI2694518T1 (enExample)
SM (1) SMT201500322B (enExample)
TN (1) TN2013000377A1 (enExample)
TW (1) TWI516265B (enExample)
UA (1) UA110131C2 (enExample)
WO (1) WO2012131379A1 (enExample)
ZA (1) ZA201307085B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922858A4 (en) * 2012-11-20 2016-06-15 Univ Mcgill THIENOPYRIMIDININHIBITORS OF FARNESYL AND / OR GERANYL GERANYL PYROPHOSPHATE SYNTHASE
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
BR112019027640A2 (pt) 2017-06-21 2020-07-07 SHY Therapeutics LLC composto, método para testar a capacidade de um ou mais compostos, método para inibir a função de ras, método para inibir a função de rho, método para inibir a função de rac, composição farmacêutica
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
EP0846119B1 (en) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
AU713573B2 (en) 1996-07-26 1999-12-02 Nissan Chemical Industries Ltd. Chroman derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク. カリウムチャネル阻害剤
WO2000012492A1 (en) 1998-09-01 2000-03-09 Nissan Chemical Industries, Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
WO2001021609A1 (en) 1999-09-24 2001-03-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2393756A1 (en) 1999-12-21 2001-06-28 Aimee D. Reed Potassium channel inhibitors
DE60132606T2 (de) 2000-09-20 2009-02-19 Merck & Co., Inc. Isochinolinone als kalium-kanal-inhibitoren
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002062343A2 (en) 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
CA2450541A1 (en) 2001-06-25 2003-01-03 Nissan Chemical Industries, Ltd. Substituted benzopyran derivatives against arrhythmia
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
DK1641803T3 (da) 2003-06-11 2009-06-29 Xention Ltd Thienopyrimidinderivater som kaliumkanalinhibitorer
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
JP2007517793A (ja) 2004-01-06 2007-07-05 大正製薬株式会社 環状アミノ基によって置換されたチエノピリミジン及びチエノピリジン誘導体
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
JP2009539988A (ja) 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
CU24173B1 (es) 2016-04-25
JP5826374B2 (ja) 2015-12-02
TW201244720A (en) 2012-11-16
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
IL228555A0 (en) 2013-12-31
BR112013025236A2 (pt) 2019-09-24
US20140206703A1 (en) 2014-07-24
TWI516265B (zh) 2016-01-11
UA110131C2 (ru) 2015-11-25
JP2014509637A (ja) 2014-04-21
EP2694518B1 (en) 2015-10-07
CA2831493A1 (en) 2012-10-04
EA201301111A1 (ru) 2014-02-28
PT2694518E (pt) 2016-02-05
SG193578A1 (en) 2013-10-30
CR20130488A (es) 2013-12-06
HK1193806A1 (zh) 2014-10-03
AU2012235882B2 (en) 2015-08-06
CL2013002789A1 (es) 2014-07-18
WO2012131379A1 (en) 2012-10-04
HRP20151340T1 (hr) 2016-02-26
SI2694518T1 (sl) 2016-02-29
HUE028438T2 (en) 2017-02-28
EP2694518A1 (en) 2014-02-12
PH12013501952A1 (en) 2018-04-11
AU2012235882A1 (en) 2013-05-02
CU20130124A7 (es) 2014-01-29
US9249155B2 (en) 2016-02-02
AP2013007198A0 (en) 2013-10-31
HK1193096A1 (zh) 2014-09-12
CN103492392A (zh) 2014-01-01
PE20141021A1 (es) 2014-08-30
ZA201307085B (en) 2015-04-29
RS54458B1 (sr) 2016-06-30
MX335937B (es) 2016-01-04
AR088735A1 (es) 2014-07-02
NZ615621A (en) 2015-01-30
ME02314B (me) 2016-06-20
SMT201500322B (it) 2016-02-25
NI201300100A (es) 2014-01-07
DK2694518T3 (en) 2015-11-09
CY1117025T1 (el) 2017-04-05
ES2558563T3 (es) 2016-02-05
GT201300225A (es) 2014-12-30
CN103492392B (zh) 2015-11-25
CO6801756A2 (es) 2013-11-29
PL2694518T3 (pl) 2016-03-31
GB201105659D0 (en) 2011-05-18
MX2013011301A (es) 2014-04-16
ECSP13012988A (es) 2013-12-31
KR20140023332A (ko) 2014-02-26

Similar Documents

Publication Publication Date Title
MA39092A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
CA2871471C (en) Dna-pk inhibitors
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
MA33670B1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
UA114001C2 (xx) Оксазолідин-2-он-піримідинові похідні
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA35064B1 (fr) Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
GEP201706657B (en) Quinoline derivatives as pde10a enzyme inhibitors